In addition, PMX205 and Avacopan (CCX168), which are C5aR1 antagonists are also under clinical development for amyotrophic lateral sclerosis (38) and atypical uremic hemolytic syndrome (aUHS), anti-neutrophil cytoplasmic antibody associated (ANCA) vasculitis, and immunoglobulin A (IgA) nephropathy (19), respectively, thus also representing other potential therapeutic medicines for envenomation treatment. This evidence concerns the gene C5AR1 and vasculitis.